Search Results - "Lipka, L.J."

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia by Knopp, R.H., Gitter, H., Truitt, T., Bays, H., Manion, C.V., Lipka, L.J., LeBeaut, A.P., Suresh, R., Yang, B., Veltri, E.P.

“…Aims This randomized, double-blind, placebo-controlled, parallel-group study evaluated the safety and efficacy of ezetimibe 10mg/day in patients with primary…”
Get full text

Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia by Ballantyne, C M, Lipka, L J, Sager, P T, Strony, J, Alizadeh, J, Suresh, R, Veltri, E P

“…Long-term safety and tolerability of ezetimibe plus atorvastatin (EZE + ATV) coadministration therapy were compared to those of ATV monotherapy in patients…”
Get more information

Effect of ezetimibe on serum concentrations of lipid-soluble vitamins by Knopp, R.H., Bays, H., Manion, C.V., Lipka, L.J., Melani, L., LeBeaut, A.P., Suresh, R., Veltri, E.P.

Get full text

Ezetimibe does not decrease the response to cosyntropin stimulation by Bays, H., Knopp, R.H., Mardon, C.V., Lipka, L.J., LeBeaut, A.P., Suresh, R., Veltri, E.P.

Get full text

Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomized, double-blind, placebo-controlled trial by Knopp, R.H., Gitter, H., Truitt, T., Lipka, L.J., LeBeaut, A.P., Suresh, R., Veltri, E.P.

Get full text